Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00532064 · ClinicalTrials.gov registry record
Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- 55
- Enrollment target
NCT00532064: Clinical Trial study, sponsored by M.D. Anderson Cancer Center.
NCT00532064 is a clinical trial that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00532064 was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- 55 participants
- Enrollment target
Study Summary
This trial studies how well cardiac biomarkers work in the early detection of cardiotoxicity in patients receiving sunitinib malate or sorafenib chemotherapy. Some chemotherapies are known to cause damage to heart muscle cells, resulting in heart failure. Often, the damage is not detected until heart failure has already occurred. Testing for cardiac biomarkers, such as troponin I and/or T and B-type natriuretic peptide (BNP), may be useful in detecting heart damage earlier than other tests currently performed (such as echocardiogram and electrocardiogram).
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Questionnaire Administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2007-09-12 |
| Est. Completion | 2018-05-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00532064
The ClinicalTrials.gov registry entry for NCT00532064 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT00532064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00532064 about?
NCT00532064 is a clinical study titled "Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy". This trial studies how well cardiac biomarkers work in the early detection of cardiotoxicity in patients receiving sunitinib malate or sorafenib chemotherapy. Some chemotherapies are known to cause damage to heart muscle cells, resulting in heart failure. Often, the damage is not detected until hear...
What is the current status of trial NCT00532064?
This trial is currently terminated. The enrollment target is 55 participants. The study started on 2007-09-12. Estimated completion is 2018-05-02.
What interventions are being tested in trial NCT00532064?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT00532064?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.